



(Print)

JUC Vol. 18(2), 24-36 (2022). Periodicity 2-Monthly



(Online)



Estd. 2005

JOURNAL OF ULTRA CHEMISTRY

An International Open Free Access Peer Reviewed Research Journal of Chemical Sciences and Chemical Engineering

website:- www.journalofchemistry.org

A systematic review on diverse synthetic route and pharmacological activities of benzimidazole as optimized lead

SHANKAR THAPA^{1*}, SACHINDRA L. NARGUND¹ and
MAHALAKSHMI SURESHA BIRADAR¹

¹Department Of Pharmaceutical Chemistry, Nargund College of Pharmacy, Rajiv Gandhi
University of Health Sciences, Bengaluru-560085 (India)

Corresponding Author Email:- tshankar551@gmail.com

<http://dx.doi.org/10.22147/juc/180202>

Acceptance Date 20th June, 2021,

Online Publication Date 28th June, 2022

Abstract

The aim of this review is to provide the systematic information of synthetic scheme and biological activity of synthesized benzimidazole derivatives. Benzimidazole is widely used lead molecule for the synthesis of various types of pharmacologically active moiety. It is heterocyclic aromatic fused colorless solid having molecular mass of 118.053 g/mol. It is basic in nature and can be served as ligand in coordination chemistry. It is bioactive compound showed various pharmacological activity till now viz. anthelmintics (albendazole, mebendazole), proton pump inhibitors (omeprazole, pantoprazole), antibiotics, antiprotozoal, antifungal, anti-cancer, anti-viral, anti-oxidant, anti-inflammatory *etc.* Various synthetic route by various methods is also already reported. Some of them are traditional convenient method, microwave reactor method, solvent free synthesis method, green synthesis method. Due to its wide variety of biological action and the similarity with biomolecule, it is frequently taken as lead for new drug discovery.

Key words : benzimidazole derivatives, bioactive, anti-cancer, anti-viral, antibiotic.


1. Introduction

Benzimidazole has been used, in various drug discovery process to enhance the value of

pharmacological activity, as pharmacophore¹. It is the basic and most used top five hetero-aromatic five-membered nitrogen containing pharmacophore². Benzimidazole is highly stable molecule which is


This is an open access article under the CC BY-NC-SA license (<https://creativecommons.org/licenses/by-nc-sa/4.0/>)

not affected by the treatment of conc. acid as well as high temperature. The ring is stable enough for the oxidative cleavage³. This scaffold is frequently taken as lead moiety in the field of drug design because of structural similarity to the various biological molecule present inside the body and also act as secondary bio isosteres of nucleobase⁴. Benzimidazole substructures are the privileged bioactive compound as they possess anti-bacterial, anti-viral, anti-cancer, cytotoxic, anti-oxidant, anti-helminthic, anti-inflammatory, analgesic, anti-protozoal, anti-fungal, anti-hypertensive, immunosuppressant and many more other therapeutical activities⁵⁻⁷. It shows potential inhibitory function on SARS-CoV-2 protease and glycoprotein⁸. Molecular interaction of the lead molecule gives an idea about the possibility of new target and binding pocket for the optimized benzimidazole moiety^{9,10}.



1.1. Phillips Method of Synthesis

Usually, it is difficult to synthesis the benzimidazole by simple heating the component together. This problem was solved by the improved Phillips method for synthesizing the benzimidazole by using dilute mineral acid at lower temperature with o-phenylenediamine and organic acid as starting materials (scheme 1). The yield of this method can be increase by the use of aromatic acid also^{11,12}.




2. Verified Synthetic Scheme

2.1. Monosubstituted Derivatives :

Yusuf Ozkay *et al* synthesized 12 new derivative of benzimidazole- hydrazone as potential

antibacterial and antifungal compounds. They followed the four steps pathway to synthesized the derivatives of yield in the range of 68 to 81% (scheme 2).




Compound 4b, 4d, 4e and 4g showed the maximum response as antibacterial activity against human pathogen. Meanwhile same compounds showed the reasonable response towards fungal species. It was concluded that the halogen bearing derivatives showed the higher level of antibacterial activity (e.g., 4d, 4e, 4f)¹³.

Yeong Keng Yoon *et al.* prepared seven novel benzimidazole derivatives by using 4-chloro-3-nitrobenzoic acid as starting material (scheme 3). They screened all the derivatives for the antimycobacterial activity against *Mycobacterium tuberculosis*. They kept constant substitution at N-1 position making C-2 position variable for

different possible substitution. So, the synthesized compounds were considered as monosubstituted derivatives.

Table 1. Substitution and for scheme 2 and their yield

Compound	R	Yield
4b	H	81%
4c	OH	74%
4d	Cl	69%
4e	Br	-
4f	F	-
4g	COOH	80%
4k	N(CH ₃) ₂	77%



Scheme 3


From the screened data it was concluded that compound ST02, ST03, ST04 showed maximum antimycobacterial activity against *Mycobacterium tuberculosis*¹⁴.

Table 2. Substitution for scheme 3 and their yield

Compound	R	Yield
ST02		85%
ST03		90%
ST04		66%

Akabar Mobinikhaledi *et al.* developed the procedure for the synthesis of benzimidazole derivatives as α -glycosidase inhibitors. Phthalic anhydride was used as protecting agent to


synthesize the starting material, N-protected amino acids. Then, substituted benzimidazole was synthesized by o-phenylenediamine and N-protected amino acid (scheme 4).




Scheme 4

Yeast and rat intestinal α -glycosidase enzyme is used to test the inhibitory effect of the synthesized compounds. Among all the screened compound only 2-(1-(1H-benzo(d)imidazol-2-yl)-2-phenylethyl) isoindoline-1, 3-dione and 2-(1-(1H-benzo(d)imidazol-2-yl)-2-(4-hydroxyphenyl) ethyl) isoindoline-1,3-dione displayed significant result for inhibition of enzyme¹⁵.

Srinivas Rao Dasari *et al.* synthesized antibacterial benzimidazole based pyrazole derivatives. 2-butyl-4-chloro-1H-imidazole-5-carbaldehyde and acetophenone is used for the synthesis and the compounds are confirmed by IR, Mass spectroscopy, and NMR data studies (scheme 5).




Scheme 5




They evaluated the anti-bacterial activity against gram +ve and gram -ve strain by using streptomycin (100µg/ml) as reference. Compound ST10 was found to express high antibacterial

activity. Compare to reference ST11 and ST12 also showed excellent activity. These compound also were screened for molecular docking studies¹⁶.



Keerthana Bacharaju *et al* synthesized key benzimidazole derivatives substituted with dithiocarbonate and evaluated as anticancer agent. Chloro acetic acid and o-phenylenediamine are

used for the synthesis. And later various amine and carbon disulphide were used for derivatives synthesis (scheme 6).




Scheme 6

Chick pea seed (*Cicer arietinum*) was used for evaluation of antimitotic activity and compound ST13 only showed the highest potency for antimitotic activity. All the synthesized compounds were tested for molecular docking¹⁷.

Kamatchi Chandrasekar *et al.* performed

the docking studies against topoisomerase II/ DNA gyrase enzyme and also synthesized the docked benzimidazole ligand in lab. They synthesized novel benzimidazole derivatives from the mixture of o-phenylenediamine and formic acid by reflux (scheme 7).




Scheme 9


Compound substituted with electron withdrawing group and electron donating group on benzine ring exhibit different antibacterial activity. The compound ST21 and ST22 displayed better activity than reference compound Gentamycin. The docking score also recorded against the topoisomerase-II enzyme²⁰.

1.1. Disubstituted Derivatives:

Rezk R. Ayyad *et al.* synthesized ten novel disubstituted benzimidazole derivatives and tested for the anti-inflammatory & analgesic activity. They used phenylenediamine and p-hydroxy benzaldehyde as reactant to synthesized the derivatives (scheme 10).




Scheme 10



From the synthesized ten compounds, they found

compound ST01 exhibits maximum anti-inflammatory and analgesic activity⁽²¹⁾. Abdelaaziz Ouahrouch *et al.*, developed new disubstituted derivatives keeping benzimidazole as lead optimized and evaluated for pharmacological activity. They synthesized hybrid molecule by the condensation reaction of 4-(trimethylsilyl)ethynyl benzaldehyde and o-phenylenediamine in presence of $\text{Na}_2\text{S}_2\text{O}_5$ (scheme 11). All the compound found above 90% yield.




Scheme 11

Out of all compounds a modest inhibition was found with compound ST05 which is CF₃ substituted derivative. Compound ST06 and ST07 also perform good pharmacological action²².


Table 3. Substitution for scheme 11 and their yield

Compound	R	R ¹	Yield
ST05	CF ₃	H	95%
ST06	F	H	98%
ST07	Cl	Cl	95%


Ankita Rathore *et al.*, discovered new analogue of extended benzimidazole derivatives and evaluated in-vitro selective cyclooxygenase (COX1 & COX2) inhibitory activity. They used o-phenylenediamine and 2-chloro ethanoic acid as starting material (scheme 12).



Compound 51 was emerged the lead compound as it is the most potent and selective COX-2 inhibitor. This compound also has less gastric toxicity and could be developed further as new lead optimized compound for the same²³.




Monika *et al* synthesized di-substituted methylated benzimidazole derivatives from 2-chloro-5-methyl nitrobenzene and aryl/alkylamine (scheme 13).




Scheme 13 The benzimidazole having cyclohexyl substitution showed excellent antibacterial activity. Between the synthesized

compound, ST17 and ST18 showed good antibacterial activity against both the gram +ve and gram -ve bacteria²⁴.



Gopal K. Padhy *et al* developed the new disubstituted benzimidazole derivatives for antimicrobial activity. They used multi-step reaction


method of 1,2-phenylenediamine with 2-hydroxy propanoic acid to synthesize the derivatives (scheme 14).



Scheme 14

The compound ST20 showed very good antibacterial activity against *S. aureus* and *B.*


subtilis. The remaining other synthesized compound indicate poor activity²⁵.



1.1. Trisubstituted Derivatives

Joanna Matysiak *et al.*, synthesized novel benzimidazole derivatives modifying both the ring and their efficacy had been determined as AchE and BuchE inhibitor. The result of the compounds

was supported by docking simulation studies simultaneously. 1,2-diamine and sulfinylbis [(2,4-dihydroxy phenyl) methanethione]-{STB} were used for the one step synthesis reaction (scheme 15). The percentage yield was found in between 60% to 87%.




Scheme 15

X, Y, Z = H for ST08 & X, Z = H and Y = OMe for ST09

Compound substituted with electron withdrawing groups showed the highest inhibitory action. Therefore, compound ST08 and ST09 are strongest inhibitor at the same time analogue ST09 is more active against BuchE²⁶.

Compound	R ¹	R ²	R ³
ST08	H	Cl	H
ST09	Me	H	H


Kevin J. Moriarty *et al* studied the interleukin-2T-cell kinase (Itk) inhibitory action of trisubstituted benzimidazole derivatives. They used the synthetic scheme of 4-fluoro-3-nitro phenylamine with cyclohexane carbonyl chloride for the preparation of derivatives (scheme 16).



Scheme 16

From the docking studies they found compound ST13 has potential feature to become


hit and they also studied the SAR of the derivatives²⁷.




Scheme 17

Compound ST15 and ST16 showed good antifungal activity discovered after screening against fungus. Their activity was found close to the reference compound ketoconazole. Docking score of the compound 10f and 10l had been justifiable for the interaction(28).

Compound	R ¹	R ²	R ³
ST15	H	CH ₃	Phenyl
ST16	Cl	H	Phenyl



Juan Valdez *et al* prepared halogenated and non-halogenated tri-substituted benzimidazole derivatives and screened for antiparasitic activity. The Phillips method was used for the synthesis of most of the 1H-benzimidazole. 1,2-phenylenediamine is refluxed with acetic acid for 3-4 hr. (scheme 18).



Scheme 18

Metronidazole and albendazole were used as reference for testing antiparasitic activity. Among all screened compounds, it was found that compound with no substitution in the benzoic ring

i.e. ST19 and compound having methylthio group at 2-position and chlorine at 5-position i.e. ST19 were most significant activity²⁹.

ST18: No Substitution

ST19: $R_1 = \text{Cl}$ $R_2 = \text{H}$ $R_3 = \text{SH}$

1. Conclusion

This article collected various original article published from past and reviewed the synthetic route and pharmacological activity with molecular docking score of benzimidazole derivatives as optimized lead in the field of research and synthetic chemistry. It can be report that different heterocyclic, aromatic, alkyl and branched chain substitution can be attached to the lead benzimidazole to obtained the novel derivatives with improve therapeutic properties. The weak molecular interaction with protein can be enhanced by electron-rich nitrogen heterocycles and can be justify the proton receiving and donating property of the compound. The position C-2 in the ring is very much prone to substitution and show significance antibacterial and anti-tumours activity. Position C-5 and C-6 is good for the small side chain or Cl and F can incorporate to optimize the physiochemical parameters. Thus, benzimidazole behave as important optimized lead compound for wide range pharmacological activity.

2. Scope of future research

Benzimidazole is versatile lead moiety having a great scope in almost all the pharmacological activity. The activity of benzimidazole can be more expand in the field of enzyme inhibition and disease pathway breaking. More environmentally friendly synthetic route can be evaluated to enhance the scope of it in green chemistry. The present review was more focus on the traditional synthetic route but its evaluation on molecular docking and molecular dynamic level can be future scope. Detail study on docking properties of benzimidazole and nano particle catalysed

synthesis of it will be interesting to see in future.

3. Acknowledgment

We sincerely thank management of Nargund college of pharmacy for their support. Our sincere thank go to Dr. Ranjit Kaur.

4. Funding

There is no funding support for the project.

5. Conflict of Interest

All authors declare that there is no conflict of interest.

Reference

1. Shah K, Chhabra S, Shrivastava SK, Mishra P. Benzimidazole: A promising pharmacophore. *Med Chem Res.*; 22(11): 5077–104 (2013).
2. Faheem M, Rathaur A, Pandey A, Kumar Singh V, Tiwari AK. A Review on the Modern Synthetic Approach of Benzimidazole Candidate. *ChemistrySelect.*; 5(13): 3981–94 (2020).
3. Singh PK, Silakari O. Benzimidazole: Journey From Single Targeting to Multitargeting Molecule. *Key Heterocycle Cores for Designing Multitargeting Molecules*. Elsevier Ltd; 31–52 p (2018).
4. Kamanna K. Synthesis and Pharmacological Profile of Benzimidazoles. In: *Chemistry and Applications of Benzimidazole and its Derivatives*. p. 1–9 (2019).
5. Kumar U, Narang R, Nayak SK, Singh SK, Gupta V. Benzimidazole: Structure activity relationship and mechanism of action as antimicrobial agent. *Res J Pharm Technol.*; 10(7): 2400–14 (2017).
6. Kūçūkbay H, Uçkun M, Apohan E, Yeşilada

- Ö. Cytotoxic and antimicrobial potential of benzimidazole derivatives. *Arch Pharm (Weinheim)*; 354(8): 1–8 (2021).
7. Rao TN, Alomar SY, Ahmed F, Albalawi F, Ahmad N, Rao NK, *et al.* Reusable nano-zirconia-catalyzed synthesis of benzimidazoles and their antibacterial and antifungal activities. *Molecules*; 26(14): 2–14 (2021).
 8. Khan S, Kale M, Siddiqui F, Nema N. Novel pyrimidine-benzimidazole hybrids with antibacterial and antifungal properties and potential inhibition of SARS-CoV-2 main protease and spike glycoprotein. *Digit Chinese Med*; 4(2): 102–19 (2021).
 9. Serafini M, Torre E, Aprile S, Grosso E Del, Gesù A, Griglio A, *et al.* Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to in Vivo Pharmacodynamic Activity. *J Med Chem*; 63(6): 3047–65 (2020).
 10. Jimoh TA, Oyewale AO, Ibrahim H, Habila JD, Arthur DE. Biological Evaluation and Docking Study of Synthesized Derivatives of Benzotriazole and Benzimidazole as Antibacterial Agents. *Chem Africa [Internet]*. 2022; Available from: <https://doi.org/10.1007/s42250-022-00348-x>
 11. Madawali I, Gaviraj EN, Kalyane N V, Shivakumar B. A Review On Substituted Benzimidazoles/ : Biologically Active Compounds.; 9 (2019).
 12. Li X, Zhang J, Yang Y, Hong H, Han L, Zhu N. Reductive cyclization of o-phenylenediamine with CO₂ and BH₃NH₃ to synthesize 1H-benzimidazole derivatives. *J Organomet Chem*; 954–955: 122079 (2021).
 13. Ozkay Y, Tunali Y. Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety. *Eur J Med Chem*; 45(2010): 3293–8 (2010).
 14. Yoon YK, Ali MA, Choon TS, Ismail R, Wei AC, Kumar RS, *et al.* Antituberculosis/ : Synthesis and Antimycobacterial Activity of Novel Benzimidazole Derivatives. *BoMed Res Int*; 2013: 1–6 (2013).
 15. Akbar M, Behvar A. Design and Synthesis of New Benzimidazole and Pyrimidine Derivatives as α -glucosidase Inhibitor. *Indian J Pharm Res*; 14(3): 723–31 (2015).
 16. Dasari S, Tondepu S. Design, Synthesis and Molecular Docking Studies of Novel Pyrazole Benzimidazole Derivatives as Potent Antibacterial Agents. *Asian J Chem*; 31(12): 2733–9 (2019).
 17. Bacharaju K, Reddy S, Sivan S, Jyostnatangeda S. Design, synthesis, molecular docking and biological evaluation of new dithiocarbamates substituted benzimidazole and chalcones as possible chemotherapeutic agents. *Bioorg Med Chem Lett*; 22: 3274–7 (2012).
 18. Chandrasekar K, Kumar B, Saravanan A. Evaluation and Molecular Docking of Benzimidazole and its Derivatives as a Potent Antibacterial Agent. *Biomed Pharmacol J*; 12: 1835–47 (2019).
 19. Devkate CG, Warad KD, Bhalerao MB, Digambar D, Siddique MIM. Green and Efficient Synthesis of Benzimidazole Derivatives and their Antibacterial Screening. *J Chem Pharm Res*; 9(8): 209–13 (2017).
 20. Gullapelli K, Brahmeshwari G, Ravichander M, Kusuma U. Synthesis, antibacterial and molecular docking studies of new benzimidazole derivatives. *Egypt J Basic Appl Sci*; 1–7 (2017).
 21. Ayyad RR, Sakr HM, El-gamal KM, Eissa IH, Ha A, El-raheim ASA, *et al.* Anti Inflammatory, Proton Pump Inhibitor and Synthesis of Some New Benzimidazole Derivatives. *Der Chem Sin*; 8(1): 168–81 (2017).
 22. Ouahrouch A, Ighachane H, Taourirte M, Engels JW. Full Paper Benzimidazole-1, 2, 3-triazole Hybrid Molecules/ : Synthesis and Evaluation for Antibacterial / Antifungal

- Activity. *arch.pharm.chem.life Sci.*; *347*: 1–8 (2014).
23. Rathore A, Rahman MU, Siddiqui AA, Ali A. Design and Synthesis of Benzimidazole Analogs Endowed with Oxadiazole as Selective COX-2 Inhibitor. *Arch.pharm.chem.life sci.*; *347*: 923–35 (2014).
24. Monika, Kaur R. Synthesis and antimicrobial activities of novel benzimidazole derivatives. *Indo Am J Pharm Sci.*; *05(01)*: 706–11 (2018).
25. Padhy GK, Panda J, Behera AK. Synthesis and characterization of novel benzimidazole chalcones as antibacterial agents. *Der pharma Chem pharma Chem.*; *8(13)*: 235–41 (2016).
26. Matysiak J, Alicja S. Biological Evaluation, Molecular Docking, and SAR Studies of Novel 2- (2 , 4-Dihydroxyphenyl) -1 H - Benzimidazole Analogues. *Biomolecules.*; *9(870)*: 1–17 (2019).
27. Moriarty KJ, Takahashi H, Pullen SS, Hnin H, Sallati RH, Raymond EL, et al. Discovery, SAR and X-ray structure of 1 H -benzimidazole-5-carboxylic acid cyclohexyl-methyl-amides as inhibitors of inducible T-cell kinase (Itk). *Bioorg Med Chem Lett.*; *18*: 5545–9 (2008).
28. Kankate RS, Gide PS, Belsare DP, Kankate RS. Microwave assisted synthesis, antifungal evaluation and molecular docking of benzimidazole derivatives. *Der pharma Chem.*; *6(6)*: 396–405 (2014).
29. Valdez J, Cedillo R, Herna A, Navarrete-va G, Herna F, Herna M, *et al.* Synthesis and Antiparasitic Activity of 1 H -Benzimidazole Derivatives. *Bioorg Med Chem Lett.*; *12*: 2221–4 (2002).